Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.
The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.
The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.
Hormone replacement therapy with spironolactone and estradiol significantly improved hair thickness and growth, surpassing previous treatments like dutasteride, finasteride, and minoxidil. The user experienced regrowth in receded areas and a more youthful appearance.
The user has tried RU58841, pyrilutamide, oral minoxidil combined with finasteride or dutasteride for hair loss. They are asking for new and exciting treatments.
Minoxidil, finasteride, and RU58841 promote hair growth by different mechanisms, with minoxidil and prostaglandin E1 being specifically mentioned. Corticosteroids can also cause hair growth.
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
Prostaglandin balance affects hair loss, particularly in conditions like Lichen Planopilaris, where an imbalance can lead to hair follicle damage. Treatments mentioned include prostaglandin analogs and Pioglitazone HCL, with a focus on maintaining prostaglandin equilibrium for potential hair regrowth.
The conversation discusses using natural DHT blockers like saw palmetto, beta sitosterol, pumpkin seed oil, pygeum africanum bark, and nettle root as alternatives to finasteride for hair loss, with mixed opinions on their effectiveness. Some users report minimal improvement with natural options and better results with finasteride or dutasteride, despite concerns about potential side effects.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.
User is considering switching from finasteride to dutasteride and adding pyrilutamide for hair loss treatment. Other users recommend dutasteride for its effectiveness and suggest adding pyrilutamide.
The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.
The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
Two different experiences of using Pyrilutamide, a hair loss treatment, which caused headaches that took around a week to subside in both cases. Other users offered insight into their own experiences with the treatment or suggested alternate treatments such as RU58841 and Minoxidil.
Saw palmetto and pumpkin seed oil are generally considered ineffective for hair regrowth compared to finasteride and minoxidil. Users report that finasteride, minoxidil, and sometimes dutasteride are more reliable for maintaining and regrowing hair.
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
Copper peptides are discussed as a potential alternative to minoxidil for treating hair loss. Users share interest and challenges in accessing copper peptides, with some mentioning specific products.